Proteomics of bronchial biopsies: Galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients

Pierluigi Mauri(Institute of Biomedical Technologies), Giorgio Walter Canonica(Humanitas University), A Riccio(University of Palermo), Rossana Rossi(University of Parma), Stephen T. Holgate(University of Southampton), Louise Benazzi(Institute of Genetic and Biomedical Research), Roberto W. Dal Negro, Laura De Ferrari(Istituti di Ricovero e Cura a Carattere Scientifico), Dario Di Silvestre(Institute of Biomedical Technologies)
Immunology Letters
September 5, 2014
10.1016/j.imlet.2014.08.010
Cited by 101

Related Papers

The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
The <scp>EAACI</scp>/<scp>GA</scp><sup>2</sup><scp>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update
|Allergy|2014|1.2k
Benefits of omalizumab as add‐on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
|Allergy|2004|1.1k
Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness
|Nature|2002|1.1k
Treatment strategies for allergy and asthma
|Nature reviews. Immunology|2008|687